文献速递甲状腺疾病肥胖与代谢综合征

代谢功能障碍相关脂肪性肝病与甲状腺癌的关联

Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer.
PubMed 文献 · Thyroid · 2024-12-18

该研究基于韩国国家健康筛查计划2009至2010年214,502名40岁及以上成年人队列,随访平均9.61年,比较无心血管代谢危险因素(CMRF)且无脂肪性肝病(SLD)、仅有CMRF、代谢功能障碍相关脂肪性肝病(MASLD)及代谢与酒精相关/相关性肝病(MetALD)四组新发甲状腺癌风险。结果显示,相较于无CMRF且无SLD者,CMRF组(HR 1.33,CI 1.16-1.52)、MASLD组(HR 1.36,CI 1.17-1.58)及MetALD组(HR 1.40,CI 1.04-1.88)甲状腺癌风险显著升高;MetALD与甲状腺癌发病的显著关联仅见于男性。

要点

  • 在韩国人群中,CMRF、MASLD和MetALD均与甲状腺癌发病率升高相关。
  • MetALD与甲状腺癌发病的显著关联仅在男性中观察到。
  • 该研究首次揭示甲状腺癌与CMRF-MASLD-MetALD连续谱之间的关联。

核心结论

  • 除CMRF外,MASLD和MetALD与韩国人群甲状腺癌发病率升高相关。
  • 该研究首次证明甲状腺癌与CMRF-MASLD-MetALD连续谱之间的关联。

研究设计与样本

  • 研究排除了有肝病史或恶性肿瘤史的个体后,分析了2009至2010年参与国家健康筛查计划的214,502名40岁及以上韩国成年人队列。
  • 参与者被分为四组:无脂肪性肝病(SLD)且无心血管代谢危险因素(CMRF)、无SLD但至少有一项CMRF、MASLD、以及代谢与酒精相关/相关性肝病(MetALD)。
  • SLD通过脂肪肝指数阈值≥30进行诊断。
  • 主要结局为随访期间新发甲状腺癌的诊断。
  • 采用多变量校正的Cox比例风险模型分析CMRF/SLD与甲状腺癌发病率的关系。

主要发现

  • 平均随访9.61年期间,共2761名参与者(1.3%)新诊断为甲状腺癌。
  • 与无CMRF且无SLD的参与者相比,有CMRF者(HR 1.33,CI 1.16-1.52)、MASLD者(HR 1.36,CI 1.17-1.58)和MetALD组(HR 1.40,CI 1.04-1.88)甲状腺癌风险显著升高。
  • MetALD与甲状腺癌发病率的显著关联仅见于男性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a hepatic manifestation of metabolic syndrome. This study investigated the association between newly developed nomenclature MASLD and the risk of thyroid cancer in the Korean population. Methods: After excluding individuals with a history of liver disease or malignancy, we analyzed a cohort of 214,502 Korean adults aged 40 years and above who participated in the National Health Screening Program from 2009 to 2010. Participants were categorized into four groups: no steatotic liver disease (SLD) without a cardiometabolic risk factor (CMRF), no SLD with at least one CMRF, MASLD, and metabolic and alcohol-related/associated liver disease (MetALD). SLD was diagnosed using a fatty liver index threshold of ≥30. The primary outcome was the diagnosis of new thyroid cancer during the follow-up period. We examined the relationship between CMRF/SLD and thyroid cancer incidence using the multivariable-adjusted Cox proportional hazards model. Results: A total of 2761 participants (1.3%) were newly diagnosed with thyroid cancer over an average follow-up of 9.61 years. Compared with participants without CMRF and SLD, those with CMRF (hazard ratio [HR] 1.33, confidence interval [CI] 1.16-1.52), those with MASLD (HR 1.36, CI 1.17-1.58), and the MetALD group (HR 1.40, CI 1.04-1.88) exhibited a significantly higher risk of thyroid cancer. In addition, MetALD is significantly associated with thyroid cancer incidence solely in men. Conclusions: In addition to CMRF, MASLD and MetALD were associated with a higher incidence of thyroid cancer in the Korean population. This study is the first to demonstrate the association between thyroid cancer and the CMRF-MASLD-MetALD continuum.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Moon SY, Son M, Cho JH, et al. Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer. Thyroid. 2024. PMID: 39692617. doi:10.1089/thy.2024.0522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。